Streetbeat News

Earnings

CRSP

CRISPR Therapeutics (NASDAQ:CRSP) reported Q1 sales of $100 million and a loss of $53.06 million, with earnings up 52.01%. The company posted a negative Return on Capital Employed (ROCE) of -0.03%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.67, beating analyst predictions of $-1.7.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:52 pm

HI

Hillenbrand (NYSE:HI) reported Q2 earnings of $463.50 million, a 869.67% increase from Q1, and sales of $691.00 million, a 5.38% increase since Q1. The company posted a return on capital employed (ROCE) of 0.28%, indicating effective capital allocation. Hillenbrand's Q2 earnings per share of $0.74 beat analyst predictions of $0.71.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:52 pm

TCMD

Tactile Systems Tech (NASDAQ:TCMD) reported Q1 sales of $58.85 million and a loss of $1.89 million, a 140.81% decrease from last quarter. The company posted a negative Return On Capital Employed (ROCE) of -0.01%, suggesting inefficient capital allocation.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:51 pm

TMCI

Treace Medical Concepts (NASDAQ:TMCI) reported Q1 sales of $42.20 million and a loss of $13.45 million, with a Return On Capital Employed (ROCE) of -0.09%. The negative ROCE suggests that management may not be effectively allocating their capital.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:51 pm

ACAD

ACADIA Pharmaceuticals reported Q1 sales of $118.46 million, but earnings decreased 3.11%, resulting in a loss of $43.02 million. The company posted a negative Return on Capital Employed (ROCE) of -0.11%, suggesting inefficient capital allocation.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:50 pm

PAY

Paymentus Holdings (NYSE:PAY) reported a 26.44% decrease in earnings from Q4, despite a 12.22% increase in sales to $148.33 million. The company posted a return on capital employed (ROCE) of 0.0% in Q1, indicating effective capital allocation. Q1 earnings per share were $0.02, beating analyst predictions of $0.0.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:50 pm

CHRS

Coherus BioSciences (NASDAQ:CHRS) reported Q1 sales of $32.44 million and a loss of $75.73 million. The company's Return on Capital Employed (ROCE) was 0.39%, indicating effective capital allocation. However, Q1 earnings per share of $-0.75 did not meet analyst predictions of $-0.57.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 2:50 pm

ZM

Zoom shares are trading lower despite the company reporting better-than-expected Q1 results.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:33 pm

WSM

Williams-Sonoma reported a Q1 FY23 revenue decline of 7.2% YoY to $1.76 billion, missing the consensus of $1.80 billion. Adjusted EPS was $2.64, above the consensus of $2.37. The company reiterated its FY23 outlook, expecting annual net revenue growth of -3% to +3% with an operating margin of 14% - 15%. WSM shares gained 3.79% to $116.42.

Portfolio Pulse from Akanksha Bakshi

May 23, 2023 | 2:32 pm

DHBUF

Delivra Health Brands Inc. (DHBUF) reported Q3 FY23 net revenue of $1.7 million, maintaining the same level as last year, with a gross profit of CA$961,000 and an adjusted EBITDA of CA$23,000. The company's stock soared following the announcement.

Portfolio Pulse from Vuk Zdinjak

May 23, 2023 | 2:19 pm